Literature DB >> 26459464

[Update on combined radio-, radiochemo-, and chemotherapy alone in multimodal therapy of nasopharyngeal carcinoma--a MAC-NPC meta-analysis].

Martina Becker-Schiebe1,2, Hans Christiansen3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26459464     DOI： 10.1007/s00066-015-0904-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  11 in total

1.  Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.

Authors:  Anne W M Lee; Stewart Y Tung; Roger K C Ngan; Rick Chappell; Daniel T T Chua; T X Lu; Lillian Siu; Terence Tan; L K Chan; W T Ng; T W Leung; Y T Fu; Gordon K H Au; C Zhao; Brian O'Sullivan; E H Tan; W H Lau
Journal:  Eur J Cancer       Date:  2010-11-26       Impact factor: 9.162

2.  Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Herbert H Loong; Brigette B Y Ma; Sing-Fai Leung; Frankie Mo; Edwin P Hui; Michael K Kam; Stephen L Chan; Brian K H Yu; Anthony T C Chan
Journal:  Radiother Oncol       Date:  2012-01-31       Impact factor: 6.280

Review 3.  Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients.

Authors:  Bertrand Baujat; Hélène Audry; Jean Bourhis; Anthony T C Chan; Haluk Onat; Daniel T T Chua; Dora L W Kwong; Muhyi Al-Sarraf; Kwan-Hwa Chi; Masato Hareyama; Sing F Leung; Kullathorn Thephamongkhol; Jean-Pierre Pignon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-01       Impact factor: 7.038

4.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

Authors:  M Al-Sarraf; M LeBlanc; P G Giri; K K Fu; J Cooper; T Vuong; A A Forastiere; G Adams; W A Sakr; D E Schuller; J F Ensley
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

5.  Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH).

Authors:  Rolf Mertens; Bernd Granzen; Lisa Lassay; Peter Bucsky; Manfred Hundgen; Gunter Stetter; Gerhard Heimann; Claudia Weiss; Clemens F Hess; Gunther Gademann
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

6.  Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Anne W M Lee; Roger K C Ngan; Stewart Y Tung; Ashley Cheng; Dora L W Kwong; Tai-Xiang Lu; Anthony T C Chan; Lucy L K Chan; Harry Yiu; Wai-Tong Ng; Frank Wong; Kam-Tong Yuen; Stephen Yau; Foon-Yiu Cheung; Oscar S H Chan; Horace Choi; Rick Chappell
Journal:  Cancer       Date:  2014-12-19       Impact factor: 6.860

7.  Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.

Authors:  Martina Buehrlen; Christian Michel Zwaan; Bernd Granzen; Lisa Lassay; Peter Deutz; Peter Vorwerk; Gundula Staatz; Günther Gademann; Hans Christiansen; Foppe Oldenburger; Miriam Tamm; Rolf Mertens
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

8.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.

Authors:  Dora L W Kwong; Jonathan S T Sham; Gordon K H Au; Daniel T T Chua; Philip W K Kwong; Ashley C K Cheng; P M Wu; Martin W M Law; Carol C H Kwok; C C Yau; K Y Wan; Raymond T T Chan; Damon D K Choy
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

9.  Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.

Authors:  X Wu; P Y Huang; P J Peng; L X Lu; F Han; S X Wu; X Hou; H Y Zhao; Y Huang; W F Fang; Y Y Zhao; C Xue; Z H Hu; J Zhang; J W Zhang; Y X Ma; W H Liang; C Zhao; L Zhang
Journal:  Ann Oncol       Date:  2013-05-09       Impact factor: 32.976

10.  Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas.

Authors:  Hendrik Andreas Wolff; Ralph M W Rödel; Bastian Gunawan; Tobias Overbeck; Markus K A Herrmann; Steffen Hennies; Andrea Hille; Hilke Vorwerk; Christoph Matthias; Clemens F Hess; Hans Christiansen
Journal:  J Cancer Res Clin Oncol       Date:  2009-07-18       Impact factor: 4.553
View more
  4 in total

1.  A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.

Authors:  Tingyu Li; Fan Yang; Kening Ma; Lijie Lv
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-31       Impact factor: 2.503

2.  Pin2 telomeric repeat factor 1-interacting telomerase inhibitor 1 (PinX1) inhibits nasopharyngeal cancer cell stemness: implication for cancer progression and therapeutic targeting.

Authors:  Chaosheng Yu; Fang Chen; Xiaoqi Wang; Zhimou Cai; Mengxue Yang; Qingwen Zhong; Jialian Feng; Junzheng Li; Congxiang Shen; Zhong Wen
Journal:  J Exp Clin Cancer Res       Date:  2020-02-07

3.  Effect of miR-25 on Proliferation of Nasopharyngeal Carcinoma Cells through Wnt/β-Catenin Signaling Pathway.

Authors:  Haixia He; Kun Yuan; Wei Chen
Journal:  Biomed Res Int       Date:  2021-08-26       Impact factor: 3.411

4.  ARHGAP42 promotes cell migration and invasion involving PI3K/Akt signaling pathway in nasopharyngeal carcinoma.

Authors:  Qian Hu; Xiao Lin; Linxiaoxiao Ding; Yinduo Zeng; Danmei Pang; Nengtai Ouyang; Yanqun Xiang; Herui Yao
Journal:  Cancer Med       Date:  2018-06-24       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.